List of chemotherapy regimens: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
mNo edit summary
mNo edit summary
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{SI}}
{{SI}}
__NOTOC__
{{Seealso|List of chemotherapeutic agents}}
{{SI}}
 
{{CMG}}; {{AE}} Ross Bonander
{{CMG}}; {{AE}} Ross Bonander


Line 12: Line 10:
{| class="wikitable"
{| class="wikitable"
! Name !! Components !! Example of uses, and other notes
! Name !! Components !! Example of uses, and other notes
 
|-
| '''7+3'''
| 7 days of Ara-C ([[cytarabine]]) plus 3 days of an [[anthracycline]] [[antibiotic]], either [[daunorubicin]] ([[DA (chemotherapy)|DA]] or [[DAC (chemotherapy)|DAC]] variant) or [[idarubicin]] ([[IA (chemotherapy)|IA]] or [[IAC (chemotherapy)|IAC]] variant)
| [[Acute myelogenous leukemia]], excluding [[acute promyelocytic leukemia]]
|-
|-
| '''[[ABVD]]''' <ref name="pmid54209">{{cite journal |author=Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C |title=Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP |journal=Cancer |volume=36 |issue=1 |pages=252–9 |year=1975 |month=July |pmid=54209 |doi= |url=}}</ref>
| '''[[ABVD]]''' <ref name="pmid54209">{{cite journal |author=Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C |title=Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP |journal=Cancer |volume=36 |issue=1 |pages=252–9 |year=1975 |month=July |pmid=54209 |doi= |url=}}</ref>
Line 26: Line 27:
| [[Breast cancer]]
| [[Breast cancer]]
|-
|-
| '''[[ADOC]]''' <ref name="pmid10555755">{{cite journal |author=Berruti A, Borasio P, Gerbino A, ''et al.'' |title=Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single institution experience |journal=Br. J. Cancer |volume=81 |issue=5 |pages=841–5 |year=1999 |month=November |pmid=10555755 |pmc=2374302 |doi=10.1038/sj.bjc.6690773 |url=}}</ref>
| '''ADOC''' <ref name="pmid10555755">{{cite journal |author=Berruti A, Borasio P, Gerbino A, ''et al.'' |title=Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single institution experience |journal=Br. J. Cancer |volume=81 |issue=5 |pages=841–5 |year=1999 |month=November |pmid=10555755 |pmc=2374302 |doi=10.1038/sj.bjc.6690773 |url=}}</ref>
| [[Doxorubicin]], [[cisplatin]], [[vincristine]], [[cyclophosphamide]]
| [[Doxorubicin]], [[cisplatin]], [[vincristine]], [[cyclophosphamide]]
| [[Thymic carcinoma]]
| [[Thymic carcinoma]]
|-
| '''BACOD'''
| [[Bleomycin]], [[doxorubicin]] (Adriamycin), [[cyclophosphamide]], [[vincristine]] (Oncovin), [[dexamethasone]]
| [[Non-Hodgkin's lymphoma]]
|-
|-
| '''[[BEACOPP]]''' <ref name="pmid9850026">{{cite journal |author=Diehl V, Franklin J, Hasenclever D, ''et al.'' |title=BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group |journal=J. Clin. Oncol. |volume=16 |issue=12 |pages=3810–21 |year=1998 |month=December |pmid=9850026 |doi= |url=}}</ref>
| '''[[BEACOPP]]''' <ref name="pmid9850026">{{cite journal |author=Diehl V, Franklin J, Hasenclever D, ''et al.'' |title=BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group |journal=J. Clin. Oncol. |volume=16 |issue=12 |pages=3810–21 |year=1998 |month=December |pmid=9850026 |doi= |url=}}</ref>
Line 34: Line 39:
| [[Hodgkin's lymphoma]]
| [[Hodgkin's lymphoma]]
|-
|-
| '''[[BEP]]'''
| '''BEP'''
| [[Bleomycin]], [[etoposide]], platinum ([[cisplatin]])
| [[Bleomycin]], [[etoposide]], platinum ([[cisplatin]])
| [[Testicular cancer]], [[germ cell tumor]]s
| [[Testicular cancer]], [[germ cell tumor]]s
|-
| '''CA'''
| [[cyclophosphamide]], [[doxorubicin]] (Adriamycin) (same as AC)
| [[Breast cancer]]
|-
|-
| '''CAF'''
| '''CAF'''
| [[Cyclophosphamide]], [[Adriamycin]]/[[Doxorubicin]], [[5-FU]]/[[Fluorouracil]]
| [[Cyclophosphamide]], [[Adriamycin]]/[[Doxorubicin]], [[5-FU]]/[[Fluorouracil]]
| [[Breast cancer]]
| [[Breast cancer]]
|-
| '''CAPOX'''
| [[Capecitabine]] and [[oxaliplatin]]
| [[Colorectal cancer]]
|-
|-
| '''CAV'''
| '''CAV'''
| [[Cyclophosphamide]], [[Adriamycin]]/[[Doxorubicin]], [[Vincristine]]
| [[Cyclophosphamide]], [[Adriamycin]]/[[Doxorubicin]], [[Vincristine]]
| [[Lung cancer]]
| [[Lung cancer]]
|-
| '''CBV'''
| [[Cyclophosphamide]], [[BCNU|BCNU (carmustine)]], VP-16 ([[etoposide]])
| [[Lymphoma]]
|-
|-
| '''CEOP-R'''
| '''CEOP-R'''
| [[Cyclophosphamide]], [[etoposide]], vincristine ([[Oncovin]]), [[prednisone]] + rituximab
| [[Cyclophosphamide]], [[etoposide]], vincristine ([[Oncovin]]), [[prednisone]] + rituximab
| [[Diffuse large B-cell lymphoma]] when patient cannot be given an anthracycline   
| [[Diffuse large B-cell lymphoma]] when patient cannot be given an anthracycline   
|-
| '''CEPP'''
| [[Cyclophosphamide]], [[etoposide]], [[procarbazine]], [[prednisone]]
| [[Non-Hodgkin's lymphoma]]
|-
| '''ChlVPP/EVA'''
| [[Chlorambucil]], [[vincristine]] (Oncovin), [[procarbazine]], [[prednisone]], [[etoposide]], [[vinblastine]], [[doxorubicin]] (Adriamycin)
| [[Hodgkin's lymphoma]]
|-
| '''CHOEP'''
| [[Cyclophosphamide]], hydroxydaunorubicin ([[doxorubicin]]), [[etoposide]], vincristine ([[Oncovin]]), [[prednisone]]
| [[Non-Hodgkin's lymphoma]]
|-
|-
| '''[[CHOP]]'''
| '''[[CHOP]]'''
| [[Cyclophosphamide]], [[doxorubicin]] ([[hydroxydoxorubicin]]), vincristine ([[Oncovin]]), [[prednisone]]
| [[Cyclophosphamide]], [[doxorubicin]] ([[hydroxydoxorubicin]]), vincristine ([[Oncovin]]), [[prednisone]]
| [[Non-Hodgkin lymphoma]]
| [[Non-Hodgkin's lymphoma]]
|-
|-
| '''[[CHOP-R]]'''
| '''CHOP-R''' or '''R-CHOP'''
| CHOP + [[rituximab]]
| CHOP + [[rituximab]]
| [[B cell]] [[non-Hodgkin lymphoma]]
| [[B cell]] [[non-Hodgkin lymphoma]]
Line 61: Line 90:
| [[Cyclophosphamide]], [[vincristine]] (Oncovin), and [[prednisone]]
| [[Cyclophosphamide]], [[vincristine]] (Oncovin), and [[prednisone]]
| Non-Hodgkin lymphoma in patients with history of [[cardiovascular disease]]
| Non-Hodgkin lymphoma in patients with history of [[cardiovascular disease]]
|-
| '''ClaPD'''
| [[Clarithromycin]], [[pomalidomide]], [[dexamethasone]]
| [[Multiple myeloma]]
|-
|-
| '''[[CMF (therapy)|CMF]]'''
| '''[[CMF (therapy)|CMF]]'''
| [[Cyclophosphamide]], [[Methotrexate]], and [[5-Fluorouracil]]
| [[Cyclophosphamide]], [[Methotrexate]], and [[5-Fluorouracil]]
| [[Breast Cancer]]
| [[Breast Cancer]]
|-
| '''CMV'''
| [[Cisplatin]], [[methotrexate]], [[vinblastine]]
| Metastatic [[transitional cell carcinoma]] of the urinary tract
|-
|-
| '''CODOX-M/IVAC''' <ref name="pmid12181251">{{cite journal |author=Mead GM, Sydes MR, Walewski J, ''et al.'' |title=An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study |journal=Ann. Oncol. |volume=13 |issue=8 |pages=1264–74 |year=2002 |month=August |pmid=12181251 |doi= |url=}}</ref>
| '''CODOX-M/IVAC''' <ref name="pmid12181251">{{cite journal |author=Mead GM, Sydes MR, Walewski J, ''et al.'' |title=An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study |journal=Ann. Oncol. |volume=13 |issue=8 |pages=1264–74 |year=2002 |month=August |pmid=12181251 |doi= |url=}}</ref>
Line 73: Line 110:
| [[Cyclophosphamide]], Oncovin (vincristine), [[procarbazine]] and prednisone
| [[Cyclophosphamide]], Oncovin (vincristine), [[procarbazine]] and prednisone
| [[Non-Hodgkin lymphoma]]
| [[Non-Hodgkin lymphoma]]
|-
| '''CT''' or '''TC'''
| [[Cyclophosphamide]] and [[docetaxel]] (Taxotere)
| [[Breast cancer]]
|-
| '''CTD'''
| [[Cyclophosphamide]], [[thalidomide]], [[dexamethasone]]
| [[AL amyloidosis]]
|-
| '''CVAD'''
| [[Cyclophosphamide]], [[vincristine]], [[doxorubicin]] (Adriamycin), [[dexamethasone]]
| Aggressive [[non-Hodgkin lymphoma]], [[lymphoblastic lymphoma]], some forms of [[leukemia]]
|-
| '''CyBorD'''
| [[Cyclophosphamide]], [[bortezomib]], [[dexamethasone]]
| [[Multiple myeloma]], [[AL amyloidosis]]
|-
|-
| '''DA-EPOCH''' <ref name="pmid11929754">{{cite journal |author=Wilson WH, Grossbard ML, Pittaluga S, ''et al.'' |title=Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy |journal=Blood |volume=99 |issue=8 |pages=2685–93 |year=2002 |month=April |pmid=11929754 |doi= |url=}}</ref>
| '''DA-EPOCH''' <ref name="pmid11929754">{{cite journal |author=Wilson WH, Grossbard ML, Pittaluga S, ''et al.'' |title=Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy |journal=Blood |volume=99 |issue=8 |pages=2685–93 |year=2002 |month=April |pmid=11929754 |doi= |url=}}</ref>
| Dose-adjusted [[Etopiside]], [[prednisone]], [[vincristine]] (Oncovin), [[Cyclophosphamide]] and doxorubicin
| Dose-adjusted [[Etopiside]], [[prednisone]], [[vincristine]] (Oncovin), [[Cyclophosphamide]] and doxorubicin
| Newly diagnosed, aggressive [[non-Hodgkin lymphoma]]
| Newly diagnosed, aggressive [[non-Hodgkin lymphoma]]
|-
| '''DCEP'''
| [[Dexamethasone]], [[cyclophosphamide]], [[etoposide]], [[platinum-based antineoplastic|platinum agent]]
| [[Multiple myeloma]]
|-
|-
| '''DHAP''' <ref name="pmid3334893">{{cite journal |author=Velasquez WS, Cabanillas F, Salvador P, ''et al.'' |title=Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP) |journal=Blood |volume=71 |issue=1 |pages=117–22 |year=1988 |month=January |pmid=3334893 |doi= |url=}}</ref>
| '''DHAP''' <ref name="pmid3334893">{{cite journal |author=Velasquez WS, Cabanillas F, Salvador P, ''et al.'' |title=Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP) |journal=Blood |volume=71 |issue=1 |pages=117–22 |year=1988 |month=January |pmid=3334893 |doi= |url=}}</ref>
Line 85: Line 142:
| Dexamethasone, cytarabine, oxaliplatin and rituximab
| Dexamethasone, cytarabine, oxaliplatin and rituximab
| Relapsed or refractory B-cell [[non-Hodgkin lymphoma]]
| Relapsed or refractory B-cell [[non-Hodgkin lymphoma]]
|-
| '''DICE'''
| [[Dexamethasone]], [[ifosfamide]], [[cisplatin]], [[etoposide]] (VP-16)
| Aggressive relapsed [[lymphomas]], progressive [[neuroblastoma]]
|-
| '''DT-PACE'''
| [[Dexamethasone]], [[thalidomide]], [[platinum-based antineoplastic|platinum agent]], [[doxorubicin]] (Adriamycin), [[cyclophosphamide]], [[etoposide]]
| [[Multiple myeloma]]
|-
|-
| '''EC'''
| '''EC'''
Line 93: Line 158:
| [[Epirubicin]], [[cisplatin]], [[fluorouracil]]
| [[Epirubicin]], [[cisplatin]], [[fluorouracil]]
| [[Gastric cancer]] and [[oesophageal cancer]]
| [[Gastric cancer]] and [[oesophageal cancer]]
|-
| '''EOX'''
| [[Epirubicin]], [[oxaliplatin]], [[capecitabine]]
| [[Esophageal cancer]], [[gastric cancer]]
|-
| '''EP'''
| [[Etoposide]], [[platinum-based antineoplastic|platinum agent]]
| [[testicular cancer]], [[germ cell tumor]]s
|-
| '''EPOCH'''
| [[Etoposide]], [[prednisone]], [[vincristine]] (Oncovin), [[cyclophosphamide]], and [[hydroxydaunorubicin]]
| [[Non-Hodgkin lymphoma]]s
|-
| '''EPOCH-R''' or '''R-EPOCH'''
| [[Etoposide]], [[prednisone]], [[vincristine]] (Oncovin), [[cyclophosphamide]], and [[hydroxydaunorubicin]] plus [[rituximab]]
| [[B cell]] [[Non-Hodgkin lymphoma]]s
|-
|-
| '''ESHAP'''
| '''ESHAP'''
| [[Etopiside]], methylprednisolone (Solu-medrol), cytarabine (ARA-C), cisplatin  
| [[Etopiside]], methylprednisolone (Solu-medrol), cytarabine (ARA-C), cisplatin  
| Relapsed or refractory [[non-Hodgkin lymphoma]]
| Relapsed or refractory [[non-Hodgkin lymphoma]]
|-
| '''ESHAP-R''' or '''R-ESHAP'''
| [[etoposide]], [[methylprednisolone]] (a [[steroid hormone]]), [[cytarabine]] (ara-C), [[platinum-based antineoplastic|platinum agent]] plus [[rituximab]]
| [[Non-Hodgkin lymphoma]]
|-
| '''FAM'''
| [[Fluorouracil]], [[doxorubicin]] (Adriamycin), [[mitomycin]]
| Metastatic small bowel adenocarcinoma
|-
| '''FCM''' or '''FMC'''
| [[Fludarabine]], [[cyclophosphamide]], [[mitoxantrone]]
| [[B cell]] non-Hodgkin lymphoma
|-
| '''FCM-R''' or '''R-FCM''' or '''R-FMC''' or '''FMC-R'''
| [[Fludarabine]], [[cyclophosphamide]], [[mitoxantrone]] plus [[rituximab]]
| [[B cell]] non-Hodgkin lymphoma
|-
| '''FM'''
| [[Fludarabine]], [[mitoxantrone]]
| [[B cell]] non-Hodgkin lymphoma
|-
| '''FMR'''
| [[Fludarabine]], [[mitoxantrone]], and [[rituximab]]
| [[B cell]] non-Hodgkin lymphoma
|-
| '''FEC'''
| [[Fluorouracil]] (5-FU), [[epirubicin]], [[cyclophosphamide]]
| [[Breast cancer]]
|-
| '''FL'''
| [[Fluorouracil]] (5-FU), leucovorin ([[folinic acid]])
| [[Colorectal cancer]]
|-
| '''FLAG'''
| [[Fludarabine]], [[cytarabine]], [[G-CSF]]
| Relapsed or [refractory [[acute myelogenous leukemia]]
|-
| '''FLAG-Ida''' or '''FLAG-IDA''' or '''IDA-FLAG''' or '''Ida-FLAG'''
| [[Fludarabine]], [[cytarabine]], [[idarubicin]], [[G-CSF]]
| Relapsed or [[refractoriness|refractory]] [[acute myelogenous leukemia]]
|-
| '''FLAG-Mito''' or '''FLAG-MITO''' or '''Mito-FLAG''' or '''MITO-FLAG''' or '''FLAMG'''
| [[Mitoxantrone]], [[fludarabine]], [[cytarabine]], [[G-CSF]]
| Relapsed or refractory [[acute myelogenous leukemia]]
|-
| '''FLAMSA'''
| [[Fludarabine]], [[cytarabine]], [[amsacrine]]
| [[Myelodysplastic syndrome]], [[acute myeloid leukemia]]
|-
| '''FLAMSA-BU''' or '''FLAMSA-Bu'''
| [[Fludarabine]], [[cytarabine]], [[amsacrine]], [[busulfan]]
| [[Myelodysplastic syndrome]], [[acute myeloid leukemia]]
|-
| '''FLAMSA-MEL''' or '''FLAMSA-Mel'''
| [[Fludarabine]], [[cytarabine]], [[amsacrine]], [[melphalan]]
| [[Myelodysplastic syndrome]], [[acute myeloid leukemia]]
|-
|-
| '''FN-D''' <ref name="pmid8648382">{{cite journal |author=McLaughlin P, Hagemeister FB, Romaguera JE, ''et al.'' |title=Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma |journal=J. Clin. Oncol. |volume=14 |issue=4 |pages=1262–8 |year=1996 |month=April |pmid=8648382 |doi= |url=}}</ref>
| '''FN-D''' <ref name="pmid8648382">{{cite journal |author=McLaughlin P, Hagemeister FB, Romaguera JE, ''et al.'' |title=Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma |journal=J. Clin. Oncol. |volume=14 |issue=4 |pages=1262–8 |year=1996 |month=April |pmid=8648382 |doi= |url=}}</ref>
Line 105: Line 242:
| Leucovorin, infusional fluorouracil, irinotecan
| Leucovorin, infusional fluorouracil, irinotecan
| Metastatic [[colorectal cancer]]
| Metastatic [[colorectal cancer]]
|-
| '''FOLFIRINOX'''
| [[Fluorouracil]] (5-FU), leucovorin ([[folinic acid]]), [[irinotecan]], [[oxaliplatin]]
| [[Pancreatic cancer]]
|-
|-
| '''[[FOLFOX]]'''
| '''[[FOLFOX]]'''
| [[Fluorouracil]], [[leucovorin]] ([[folinic acid]]), and [[oxaliplatin]]
| [[Fluorouracil]], [[leucovorin]] ([[folinic acid]]), and [[oxaliplatin]]
| [[Colorectal cancer]]
| [[Colorectal cancer]]
|-
| '''GVD'''
| [[Gemcitabine]], [[vinorelbine]], pegylated liposomal [[doxorubicin]]
| [[Hodgkin lymphoma]]
|-
| '''GemOx'''
| [[Gemcitabine]], [[oxaliplatin]]
| [[Non-Hodgkin's lymphoma]]
|-
| '''GemOx-R'''
| [[Gemcitabine]], [[oxaliplatin]], [[rituximab]]
| [[Non-Hodgkin lymphoma]]s
|-
|-
| '''HYPER-CVAD''' <ref name="pmid10561310">{{cite journal |author=Thomas DA, Cortes J, O'Brien S, ''et al.'' |title=Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia |journal=J. Clin. Oncol. |volume=17 |issue=8 |pages=2461–70 |year=1999 |month=August |pmid=10561310 |doi= |url=}}</ref>
| '''HYPER-CVAD''' <ref name="pmid10561310">{{cite journal |author=Thomas DA, Cortes J, O'Brien S, ''et al.'' |title=Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia |journal=J. Clin. Oncol. |volume=17 |issue=8 |pages=2461–70 |year=1999 |month=August |pmid=10561310 |doi= |url=}}</ref>
| Hyperfractionated cyclophosphamide, vincristine (Oncovin), doxorubicin (Adriamycin), dexamethasone ([[Decadron]])
| Hyperfractionated cyclophosphamide, vincristine (Oncovin), doxorubicin (Adriamycin), dexamethasone ([[Decadron]])
| [[Burkitt's lymphoma]]
| [[Burkitt's lymphoma]]
|-
| '''IA''' or '''IAC'''
| [[Idarubicin]] x 3 days plus Ara-C ([[cytarabine]]) x 7 days, a variant of classical [[7+3 (chemotherapy)|7+3]] regimen
| [[Acute myelogenous leukemia]], excluding [[acute promyelocytic leukemia]]
|-
|-
| '''ICE''' <ref name="pmid10577849">{{cite journal |author=Moskowitz CH, Bertino JR, Glassman JR, ''et al.'' |title=Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma |journal=J. Clin. Oncol. |volume=17 |issue=12 |pages=3776–85 |year=1999 |month=December |pmid=10577849 |doi= |url=}}</ref>'
| '''ICE''' <ref name="pmid10577849">{{cite journal |author=Moskowitz CH, Bertino JR, Glassman JR, ''et al.'' |title=Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma |journal=J. Clin. Oncol. |volume=17 |issue=12 |pages=3776–85 |year=1999 |month=December |pmid=10577849 |doi= |url=}}</ref>'
Line 133: Line 290:
| [[Methotrexate]], [[leucovorin]], [[doxorubicin]] (Adriamycin), [[cyclophosphamide]], [[vincristine]] (Oncovin), [[prednisone]], [[bleomycin]]
| [[Methotrexate]], [[leucovorin]], [[doxorubicin]] (Adriamycin), [[cyclophosphamide]], [[vincristine]] (Oncovin), [[prednisone]], [[bleomycin]]
| Non-Hodgkin lymphoma
| Non-Hodgkin lymphoma
|-
| '''MINE'''
| [[Mesna]], [[ifosfamide]], [[novantrone]], [[etoposide]]
| [[Non-Hodgkin's lymphoma]] and [[Hodgkin lymphoma]] in [[relapse]] or [[refractoriness|refractory]] cases
|-
| '''MINE-R''' or '''R-MINE'''
| [[Mesna]], [[ifosfamide]], [[novantrone]], [[etoposide]] plus [[rituximab]]
| [[Non-Hodgkin's lymphoma]] and [[Hodgkin lymphoma]] in [[relapse]] or [[refractoriness|refractory]] cases
|-
|-
| '''Mini-BEAM''' <ref name="pmid7844600">{{cite journal |author=Colwill R, Crump M, Couture F, ''et al.'' |title=Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation |journal=J. Clin. Oncol. |volume=13 |issue=2 |pages=396–402 |year=1995 |month=February |pmid=7844600 |doi= |url=}}</ref>
| '''Mini-BEAM''' <ref name="pmid7844600">{{cite journal |author=Colwill R, Crump M, Couture F, ''et al.'' |title=Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation |journal=J. Clin. Oncol. |volume=13 |issue=2 |pages=396–402 |year=1995 |month=February |pmid=7844600 |doi= |url=}}</ref>
Line 145: Line 310:
| Methotrexate, vinblastine, doxorubicin, cisplatin
| Methotrexate, vinblastine, doxorubicin, cisplatin
| [[Bladder cancer]]
| [[Bladder cancer]]
|-  
|-
| '''NABTT''' <ref name="pmid11835382">{{cite journal |author=Herrlinger U, Schabet M, Brugger W, ''et al.'' |title=German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma |journal=Ann. Neurol. |volume=51 |issue=2 |pages=247–52 |year=2002 |month=February |pmid=11835382 |doi= |url=}}</ref>  
| '''NABTT''' <ref name="pmid11835382">{{cite journal |author=Herrlinger U, Schabet M, Brugger W, ''et al.'' |title=German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma |journal=Ann. Neurol. |volume=51 |issue=2 |pages=247–52 |year=2002 |month=February |pmid=11835382 |doi= |url=}}</ref>  
| Methotrexate, calcium leucovorin; methotrexate, calcium leucovorin; methotrexate, calcium leucovorin
| Methotrexate, calcium leucovorin; methotrexate, calcium leucovorin; methotrexate, calcium leucovorin
| [[Primary central nervous system lymphoma|Primary CNS lymphoma]]
| [[Primary central nervous system lymphoma|Primary CNS lymphoma]]
|-
|-
| '''[[PCV]]''' <ref name="pmid7407756">{{cite journal |author=Levin VA, Edwards MS, Wright DC, ''et al.'' |title=Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors |journal=Cancer Treat Rep |volume=64 |issue=2-3 |pages=237–44 |year=1980 |pmid=7407756 |doi= |url=}}</ref>
| '''PCV''' <ref name="pmid7407756">{{cite journal |author=Levin VA, Edwards MS, Wright DC, ''et al.'' |title=Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors |journal=Cancer Treat Rep |volume=64 |issue=2-3 |pages=237–44 |year=1980 |pmid=7407756 |doi= |url=}}</ref>
| [[Procarbazine]], [[lomustine]] (CCNU), [[vincristine]]  
| [[Procarbazine]], [[lomustine]] (CCNU), [[vincristine]]  
| [[Brain tumors]]
| [[Brain tumors]]
Line 161: Line 326:
| [[Prednisone]], [[doxorubicin]] ([[adriamycin]]), [[cyclophosphamide]], [[etoposide]], [[cytarabine]], [[bleomycin]], [[vincristine ]](Oncovin), [[methotrexate]], [[leucovorin]]
| [[Prednisone]], [[doxorubicin]] ([[adriamycin]]), [[cyclophosphamide]], [[etoposide]], [[cytarabine]], [[bleomycin]], [[vincristine ]](Oncovin), [[methotrexate]], [[leucovorin]]
| [[Non-Hodgkin lymphoma]]
| [[Non-Hodgkin lymphoma]]
|-
| '''RdC''' or '''RCD'''
| [[Lenalidomide]] (Revlimid), [[dexamethasone]], [[cyclophosphamide]]
| [[Multiple myeloma]]
|-
|-
| '''R-DHAOx''' <ref name="urlScienceDirect - Biomedicine & Pharmacotherapy : Treatment with rituximab, dexamethasone, high-dose cytarabine, and oxaliplatin (R-DHAOx) produces a strong long-term antitumor effect
| '''R-DHAOx''' <ref name="urlScienceDirect - Biomedicine & Pharmacotherapy : Treatment with rituximab, dexamethasone, high-dose cytarabine, and oxaliplatin (R-DHAOx) produces a strong long-term antitumor effect
Line 175: Line 344:
| Methotrexate, Leucovorin, vincristine, procarbazine, methotrexate, Leucovorin
| Methotrexate, Leucovorin, vincristine, procarbazine, methotrexate, Leucovorin
| [[Primary central nervous system lymphoma|Primary CNS lymphoma]]
| [[Primary central nervous system lymphoma|Primary CNS lymphoma]]
|-
| '''RVD'''
| [[Lenalidomide]] (Revlimid), [[bortezomib]] (Velcade), [[dexamethasone]]
| [[Multiple myeloma]]
|-
|-
| '''SMILE'''
| '''SMILE'''
Line 191: Line 364:
| Paclitaxel, doxorubicin, cisplatin
| Paclitaxel, doxorubicin, cisplatin
| [[Endometrial cancer]]
| [[Endometrial cancer]]
|-
| '''TCH'''
| [[Paclitaxel]] (Taxol), [[carboplatin]], [[trastuzumab]] (Herceptin)
| [[Breast cancer]] with positive [[HER2/neu]] receptor
|-
|-
| '''Thal/Dex'''
| '''Thal/Dex'''
| [[Thalidomide]], dexamethasone
| [[Thalidomide]], dexamethasone
| Multiple myeloma
| Multiple myeloma
|-
| '''TIP'''
| [[Paclitaxel]] (Taxol), [[ifosfamide]], platinum agent [[cisplatin|cisplatin (Platinol)]]
| [[Testicular cancer]], [[germ cell tumor]]s in salvage therapy
|-
|-
| '''Treanda + Rituxan'''
| '''Treanda + Rituxan'''
Line 200: Line 381:
| Indolent and [[mantle cell lymphoma|mantle cell lymphomas]]
| Indolent and [[mantle cell lymphoma|mantle cell lymphomas]]
|-
|-
| '''[[VAD]]'''
| '''VAC'''
| [[Vincristine]], [[actinomycin]], [[cyclophosphamide]]
| [[Rhabdomyosarcoma]]
|-
| '''VAD'''
| [[Vincristine]], [[Adriamycin]] (doxorubicin), [[dexamethasone]]
| [[Vincristine]], [[Adriamycin]] (doxorubicin), [[dexamethasone]]
| [[Multiple myeloma]]
| [[Multiple myeloma]]
|-
| '''VAPEC-B'''
| [[Vincristine]], [[doxorubicin]] (Adriamycin), [[prednisone]], [[etoposide]], [[cyclophosphamide]], [[bleomycin]]
| [[Hodgkin's lymphoma]]
|-
|-
| '''VCAP-AMP-VECP''' <ref name="pmid17968021">{{cite journal |author=Tsukasaki K, Utsunomiya A, Fukuda H, ''et al.'' |title=VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801 |journal=J. Clin. Oncol. |volume=25 |issue=34 |pages=5458–64 |year=2007 |month=December |pmid=17968021 |doi=10.1200/JCO.2007.11.9958 |url=}}</ref>
| '''VCAP-AMP-VECP''' <ref name="pmid17968021">{{cite journal |author=Tsukasaki K, Utsunomiya A, Fukuda H, ''et al.'' |title=VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801 |journal=J. Clin. Oncol. |volume=25 |issue=34 |pages=5458–64 |year=2007 |month=December |pmid=17968021 |doi=10.1200/JCO.2007.11.9958 |url=}}</ref>
Line 215: Line 404:
| Etopiside, ifosfamide, cisplatin
| Etopiside, ifosfamide, cisplatin
| [[Testicular cancer]]
| [[Testicular cancer]]
|-
| '''VTD-PACE'''
| [[Bortezomib]] (Velcade), [[thalidomide]], [[dexamethasone]] plus [[platinum-based antineoplastic|platinum agent]], [[doxorubicin]] (Adriamycin), [[cyclophosphamide]], [[etoposide]]
| [[Multiple myeloma]]
|}
|}


Revision as of 05:30, 2 February 2015

WikiDoc Resources for List of chemotherapy regimens

Articles

Most recent articles on List of chemotherapy regimens

Most cited articles on List of chemotherapy regimens

Review articles on List of chemotherapy regimens

Articles on List of chemotherapy regimens in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on List of chemotherapy regimens

Images of List of chemotherapy regimens

Photos of List of chemotherapy regimens

Podcasts & MP3s on List of chemotherapy regimens

Videos on List of chemotherapy regimens

Evidence Based Medicine

Cochrane Collaboration on List of chemotherapy regimens

Bandolier on List of chemotherapy regimens

TRIP on List of chemotherapy regimens

Clinical Trials

Ongoing Trials on List of chemotherapy regimens at Clinical Trials.gov

Trial results on List of chemotherapy regimens

Clinical Trials on List of chemotherapy regimens at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on List of chemotherapy regimens

NICE Guidance on List of chemotherapy regimens

NHS PRODIGY Guidance

FDA on List of chemotherapy regimens

CDC on List of chemotherapy regimens

Books

Books on List of chemotherapy regimens

News

List of chemotherapy regimens in the news

Be alerted to news on List of chemotherapy regimens

News trends on List of chemotherapy regimens

Commentary

Blogs on List of chemotherapy regimens

Definitions

Definitions of List of chemotherapy regimens

Patient Resources / Community

Patient resources on List of chemotherapy regimens

Discussion groups on List of chemotherapy regimens

Patient Handouts on List of chemotherapy regimens

Directions to Hospitals Treating List of chemotherapy regimens

Risk calculators and risk factors for List of chemotherapy regimens

Healthcare Provider Resources

Symptoms of List of chemotherapy regimens

Causes & Risk Factors for List of chemotherapy regimens

Diagnostic studies for List of chemotherapy regimens

Treatment of List of chemotherapy regimens

Continuing Medical Education (CME)

CME Programs on List of chemotherapy regimens

International

List of chemotherapy regimens en Espanol

List of chemotherapy regimens en Francais

Business

List of chemotherapy regimens in the Marketplace

Patents on List of chemotherapy regimens

Experimental / Informatics

List of terms related to List of chemotherapy regimens

Template:Seealso Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ross Bonander

Overview

A chemotherapy regimen is a regimen for chemotherapy defining the drugs to be used, their dosage, the frequency and duration of treatments and other considerations. In modern oncology almost all regimens in use combine several chemotherapy drugs in combination chemotherapy. Acronyms often identify the individual agents used in combination chemotherapy regimens. Unfortunately, the letters used are not consistent across regimens, and in some cases (for example, "BEACOPP") the same letter is used to represent two different treatments. Because of this, there is not a naming standard for chemotherapy regimens, and this page merely represents commonly used conventions.

List of Chemotherapy Regimens

Name Components Example of uses, and other notes
7+3 7 days of Ara-C (cytarabine) plus 3 days of an anthracycline antibiotic, either daunorubicin (DA or DAC variant) or idarubicin (IA or IAC variant) Acute myelogenous leukemia, excluding acute promyelocytic leukemia
ABVD [1] Adriamycin, bleomycin, vinblastine, dacarbazine Hodgkin's lymphoma
ABVE-PC [2] Doxorubicin, bleomycin, vincristine, etoposide, prednisone, cyclophosphamide Pediatric Hodgkin's lymphoma
AC Adriamycin/Doxorubicin, Cyclophosphamide Breast cancer
ADOC [3] Doxorubicin, cisplatin, vincristine, cyclophosphamide Thymic carcinoma
BACOD Bleomycin, doxorubicin (Adriamycin), cyclophosphamide, vincristine (Oncovin), dexamethasone Non-Hodgkin's lymphoma
BEACOPP [4] Bleomycin, etoposide, Adriamycin (doxorubicin), cyclophosphamide, Oncovin (vincristine), procarbazine, prednisone Hodgkin's lymphoma
BEP Bleomycin, etoposide, platinum (cisplatin) Testicular cancer, germ cell tumors
CA cyclophosphamide, doxorubicin (Adriamycin) (same as AC) Breast cancer
CAF Cyclophosphamide, Adriamycin/Doxorubicin, 5-FU/Fluorouracil Breast cancer
CAPOX Capecitabine and oxaliplatin Colorectal cancer
CAV Cyclophosphamide, Adriamycin/Doxorubicin, Vincristine Lung cancer
CBV Cyclophosphamide, BCNU (carmustine), VP-16 (etoposide) Lymphoma
CEOP-R Cyclophosphamide, etoposide, vincristine (Oncovin), prednisone + rituximab Diffuse large B-cell lymphoma when patient cannot be given an anthracycline
CEPP Cyclophosphamide, etoposide, procarbazine, prednisone Non-Hodgkin's lymphoma
ChlVPP/EVA Chlorambucil, vincristine (Oncovin), procarbazine, prednisone, etoposide, vinblastine, doxorubicin (Adriamycin) Hodgkin's lymphoma
CHOEP Cyclophosphamide, hydroxydaunorubicin (doxorubicin), etoposide, vincristine (Oncovin), prednisone Non-Hodgkin's lymphoma
CHOP Cyclophosphamide, doxorubicin (hydroxydoxorubicin), vincristine (Oncovin), prednisone Non-Hodgkin's lymphoma
CHOP-R or R-CHOP CHOP + rituximab B cell non-Hodgkin lymphoma
COP or CVP Cyclophosphamide, vincristine (Oncovin), and prednisone Non-Hodgkin lymphoma in patients with history of cardiovascular disease
ClaPD Clarithromycin, pomalidomide, dexamethasone Multiple myeloma
CMF Cyclophosphamide, Methotrexate, and 5-Fluorouracil Breast Cancer
CMV Cisplatin, methotrexate, vinblastine Metastatic transitional cell carcinoma of the urinary tract
CODOX-M/IVAC [5] Cyclophosphamide, vincristine, doxorubicin, methotrexate (CODOX-M) + ifosfamide, etopiside (VP-16), cytarabine (Ara-C) (IVAC) Burkitt's lymphoma
COPP Cyclophosphamide, Oncovin (vincristine), procarbazine and prednisone Non-Hodgkin lymphoma
CT or TC Cyclophosphamide and docetaxel (Taxotere) Breast cancer
CTD Cyclophosphamide, thalidomide, dexamethasone AL amyloidosis
CVAD Cyclophosphamide, vincristine, doxorubicin (Adriamycin), dexamethasone Aggressive non-Hodgkin lymphoma, lymphoblastic lymphoma, some forms of leukemia
CyBorD Cyclophosphamide, bortezomib, dexamethasone Multiple myeloma, AL amyloidosis
DA-EPOCH [6] Dose-adjusted Etopiside, prednisone, vincristine (Oncovin), Cyclophosphamide and doxorubicin Newly diagnosed, aggressive non-Hodgkin lymphoma
DCEP Dexamethasone, cyclophosphamide, etoposide, platinum agent Multiple myeloma
DHAP [7] Dexamethasone, cytarabine (high-dose ARA-C), cisplatin Recurrent or refractory non-Hodgkin lymphoma
DHAX-R [8] Dexamethasone, cytarabine, oxaliplatin and rituximab Relapsed or refractory B-cell non-Hodgkin lymphoma
DICE Dexamethasone, ifosfamide, cisplatin, etoposide (VP-16) Aggressive relapsed lymphomas, progressive neuroblastoma
DT-PACE Dexamethasone, thalidomide, platinum agent, doxorubicin (Adriamycin), cyclophosphamide, etoposide Multiple myeloma
EC Epirubicin, Cyclophosphamide Breast cancer
ECF Epirubicin, cisplatin, fluorouracil Gastric cancer and oesophageal cancer
EOX Epirubicin, oxaliplatin, capecitabine Esophageal cancer, gastric cancer
EP Etoposide, platinum agent testicular cancer, germ cell tumors
EPOCH Etoposide, prednisone, vincristine (Oncovin), cyclophosphamide, and hydroxydaunorubicin Non-Hodgkin lymphomas
EPOCH-R or R-EPOCH Etoposide, prednisone, vincristine (Oncovin), cyclophosphamide, and hydroxydaunorubicin plus rituximab B cell Non-Hodgkin lymphomas
ESHAP Etopiside, methylprednisolone (Solu-medrol), cytarabine (ARA-C), cisplatin Relapsed or refractory non-Hodgkin lymphoma
ESHAP-R or R-ESHAP etoposide, methylprednisolone (a steroid hormone), cytarabine (ara-C), platinum agent plus rituximab Non-Hodgkin lymphoma
FAM Fluorouracil, doxorubicin (Adriamycin), mitomycin Metastatic small bowel adenocarcinoma
FCM or FMC Fludarabine, cyclophosphamide, mitoxantrone B cell non-Hodgkin lymphoma
FCM-R or R-FCM or R-FMC or FMC-R Fludarabine, cyclophosphamide, mitoxantrone plus rituximab B cell non-Hodgkin lymphoma
FM Fludarabine, mitoxantrone B cell non-Hodgkin lymphoma
FMR Fludarabine, mitoxantrone, and rituximab B cell non-Hodgkin lymphoma
FEC Fluorouracil (5-FU), epirubicin, cyclophosphamide Breast cancer
FL Fluorouracil (5-FU), leucovorin (folinic acid) Colorectal cancer
FLAG Fludarabine, cytarabine, G-CSF Relapsed or [refractory acute myelogenous leukemia
FLAG-Ida or FLAG-IDA or IDA-FLAG or Ida-FLAG Fludarabine, cytarabine, idarubicin, G-CSF Relapsed or refractory acute myelogenous leukemia
FLAG-Mito or FLAG-MITO or Mito-FLAG or MITO-FLAG or FLAMG Mitoxantrone, fludarabine, cytarabine, G-CSF Relapsed or refractory acute myelogenous leukemia
FLAMSA Fludarabine, cytarabine, amsacrine Myelodysplastic syndrome, acute myeloid leukemia
FLAMSA-BU or FLAMSA-Bu Fludarabine, cytarabine, amsacrine, busulfan Myelodysplastic syndrome, acute myeloid leukemia
FLAMSA-MEL or FLAMSA-Mel Fludarabine, cytarabine, amsacrine, melphalan Myelodysplastic syndrome, acute myeloid leukemia
FN-D [9] Fludarabine, mitoxantrone (Novantrone), dexamethasone Recurrent or refractory indolent non-Hodgkin lymphoma
FOLFIRI [10] Leucovorin, infusional fluorouracil, irinotecan Metastatic colorectal cancer
FOLFIRINOX Fluorouracil (5-FU), leucovorin (folinic acid), irinotecan, oxaliplatin Pancreatic cancer
FOLFOX Fluorouracil, leucovorin (folinic acid), and oxaliplatin Colorectal cancer
GVD Gemcitabine, vinorelbine, pegylated liposomal doxorubicin Hodgkin lymphoma
GemOx Gemcitabine, oxaliplatin Non-Hodgkin's lymphoma
GemOx-R Gemcitabine, oxaliplatin, rituximab Non-Hodgkin lymphomas
HYPER-CVAD [11] Hyperfractionated cyclophosphamide, vincristine (Oncovin), doxorubicin (Adriamycin), dexamethasone (Decadron) Burkitt's lymphoma
IA or IAC Idarubicin x 3 days plus Ara-C (cytarabine) x 7 days, a variant of classical 7+3 regimen Acute myelogenous leukemia, excluding acute promyelocytic leukemia
ICE [12]' Ifosfamide, carboplatin, etopiside Relapsed or primary refractory non-Hodgkin lymphoma
ICE-R ICE + rituximab Relapsed or primary refractory non-Hodgkin lymphoma
IFL [13] Irinotecan, bolus fluorouracil and leucovorin Metastatic colorectal cancer
m-BACOD Methotrexate, bleomycin, doxorubicin (Adriamycin), cyclophosphamide, vincristine (Oncovin), dexamethasone (Decadron) Non-Hodgkin lymphoma
MACOP-B [14] Methotrexate, leucovorin, doxorubicin (Adriamycin), cyclophosphamide, vincristine (Oncovin), prednisone, bleomycin Non-Hodgkin lymphoma
MINE Mesna, ifosfamide, novantrone, etoposide Non-Hodgkin's lymphoma and Hodgkin lymphoma in relapse or refractory cases
MINE-R or R-MINE Mesna, ifosfamide, novantrone, etoposide plus rituximab Non-Hodgkin's lymphoma and Hodgkin lymphoma in relapse or refractory cases
Mini-BEAM [15] Carmustine (BCNU), etopiside, cytarabine (Ara-C), melphalan Hodgkin's lymphoma (Salvage therapy, pre-transplant)
MOPP Mechlorethamine, vincristine (oncovin), procarbazine, prednisone Hodgkin's lymphoma
MVAC [16] Methotrexate, vinblastine, doxorubicin, cisplatin Bladder cancer
NABTT [17] Methotrexate, calcium leucovorin; methotrexate, calcium leucovorin; methotrexate, calcium leucovorin Primary CNS lymphoma
PCV [18] Procarbazine, lomustine (CCNU), vincristine Brain tumors
ProMACE-MOPP Methotrexate, doxorubicin (Adriamycin), cyclophosphamide, etoposide + MOPP Non-Hodgkin lymphoma
ProMACE-CytaBOM Prednisone, doxorubicin (adriamycin), cyclophosphamide, etoposide, cytarabine, bleomycin, vincristine (Oncovin), methotrexate, leucovorin Non-Hodgkin lymphoma
RdC or RCD Lenalidomide (Revlimid), dexamethasone, cyclophosphamide Multiple myeloma
R-DHAOx [19] Rituximab, dexamethasone, high-dose cytarabine, oxaliplatin Previously treated follicular lymphoma
R-FCM Rituximab, fludarabine, cyclophosphamide, mitoxantrone B cell non-Hodgkin lymphoma
RTOG 93-10 [20] Methotrexate, Leucovorin, vincristine, procarbazine, methotrexate, Leucovorin Primary CNS lymphoma
RVD Lenalidomide (Revlimid), bortezomib (Velcade), dexamethasone Multiple myeloma
SMILE Steroid (dexamethasone/prednisolone), methotrexate, ifosfamide, L-asparaganase, etopisode Advanced refractory NK/T-cell lymphoma and leukemia
Stanford V [21] Doxorubicin (Adriamycin), mechlorethamine, bleomycin, vinblastine, vincristine (Oncovin), etoposide (VP-16), prednisone Hodgkin's lymphoma
TAC [22] Docetaxel, doxorubicin, cyclophosphamide Metastatic breast cancer
TAP [23] Paclitaxel, doxorubicin, cisplatin Endometrial cancer
TCH Paclitaxel (Taxol), carboplatin, trastuzumab (Herceptin) Breast cancer with positive HER2/neu receptor
Thal/Dex Thalidomide, dexamethasone Multiple myeloma
TIP Paclitaxel (Taxol), ifosfamide, platinum agent cisplatin (Platinol) Testicular cancer, germ cell tumors in salvage therapy
Treanda + Rituxan Bendamustine, Rituximab Indolent and mantle cell lymphomas
VAC Vincristine, actinomycin, cyclophosphamide Rhabdomyosarcoma
VAD Vincristine, Adriamycin (doxorubicin), dexamethasone Multiple myeloma
VAPEC-B Vincristine, doxorubicin (Adriamycin), prednisone, etoposide, cyclophosphamide, bleomycin Hodgkin's lymphoma
VCAP-AMP-VECP [24] Vincristine, cyclophosphamide, doxorubicin, and prednisone (VCAP)--doxorubicin, ranimustine, and prednisone (AMP)-- vindesine, etoposide, carboplatin, and prednisone (VECP) Adult T-cell leukemia-lymphoma (ATLL)
VeIP [25] Vinblastine, ifosfamide, cisplatin Testicular cancer
VIP [26] Etopiside, ifosfamide, cisplatin Testicular cancer
VTD-PACE Bortezomib (Velcade), thalidomide, dexamethasone plus platinum agent, doxorubicin (Adriamycin), cyclophosphamide, etoposide Multiple myeloma

References

  1. ↑ Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C (1975). "Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP". Cancer. 36 (1): 252–9. PMID 54209. Unknown parameter |month= ignored (help)
  2. ↑ Schwartz CL, Constine LS, Villaluna D; et al. (2009). "A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425". Blood. 114 (10): 2051–9. doi:10.1182/blood-2008-10-184143. PMID 19584400. Unknown parameter |month= ignored (help)
  3. ↑ Berruti A, Borasio P, Gerbino A; et al. (1999). "Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single institution experience". Br. J. Cancer. 81 (5): 841–5. doi:10.1038/sj.bjc.6690773. PMC 2374302. PMID 10555755. Unknown parameter |month= ignored (help)
  4. ↑ Diehl V, Franklin J, Hasenclever D; et al. (1998). "BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group". J. Clin. Oncol. 16 (12): 3810–21. PMID 9850026. Unknown parameter |month= ignored (help)
  5. ↑ Mead GM, Sydes MR, Walewski J; et al. (2002). "An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study". Ann. Oncol. 13 (8): 1264–74. PMID 12181251. Unknown parameter |month= ignored (help)
  6. ↑ Wilson WH, Grossbard ML, Pittaluga S; et al. (2002). "Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy". Blood. 99 (8): 2685–93. PMID 11929754. Unknown parameter |month= ignored (help)
  7. ↑ Velasquez WS, Cabanillas F, Salvador P; et al. (1988). "Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP)". Blood. 71 (1): 117–22. PMID 3334893. Unknown parameter |month= ignored (help)
  8. ↑ Lignon J, Sibon D, Madelaine I; et al. (2010). "Rituximab, Dexamethasone, Cytarabine, and Oxaliplatin (R-DHAX) Is an Effective and Safe Salvage Regimen in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma". Clin Lymphoma Myeloma Leuk. 10 (4): 262–9. doi:10.3816/CLML.2010.n.055. PMID 20709662. Unknown parameter |month= ignored (help)
  9. ↑ McLaughlin P, Hagemeister FB, Romaguera JE; et al. (1996). "Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma". J. Clin. Oncol. 14 (4): 1262–8. PMID 8648382. Unknown parameter |month= ignored (help)
  10. ↑ Douillard JY, Cunningham D, Roth AD; et al. (2000). "Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial". Lancet. 355 (9209): 1041–7. PMID 10744089. Unknown parameter |month= ignored (help)
  11. ↑ Thomas DA, Cortes J, O'Brien S; et al. (1999). "Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia". J. Clin. Oncol. 17 (8): 2461–70. PMID 10561310. Unknown parameter |month= ignored (help)
  12. ↑ Moskowitz CH, Bertino JR, Glassman JR; et al. (1999). "Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma". J. Clin. Oncol. 17 (12): 3776–85. PMID 10577849. Unknown parameter |month= ignored (help)
  13. ↑ Saltz LB, Cox JV, Blanke C; et al. (2000). "Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group". N. Engl. J. Med. 343 (13): 905–14. PMID 11006366. Unknown parameter |month= ignored (help)
  14. ↑ Klimo P, Connors JM (1985). "MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma". Ann. Intern. Med. 102 (5): 596–602. PMID 2580468. Unknown parameter |month= ignored (help)
  15. ↑ Colwill R, Crump M, Couture F; et al. (1995). "Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation". J. Clin. Oncol. 13 (2): 396–402. PMID 7844600. Unknown parameter |month= ignored (help)
  16. ↑ von der Maase H, Hansen SW, Roberts JT; et al. (2000). "Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study". J. Clin. Oncol. 18 (17): 3068–77. Unknown parameter |month= ignored (help)
  17. ↑ Herrlinger U, Schabet M, Brugger W; et al. (2002). "German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma". Ann. Neurol. 51 (2): 247–52. PMID 11835382. Unknown parameter |month= ignored (help)
  18. ↑ Levin VA, Edwards MS, Wright DC; et al. (1980). "Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors". Cancer Treat Rep. 64 (2–3): 237–44. PMID 7407756.
  19. ↑ "ScienceDirect - Biomedicine & Pharmacotherapy : Treatment with rituximab, dexamethasone, high-dose cytarabine, and oxaliplatin (R-DHAOx) produces a strong long-term antitumor effect in previously treated patients with follicular non-Hodgkin's lymphoma".
  20. ↑ DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ (2002). "Combination chemotherapy and radiotherapy for primary central nervous system". J. Clin. Oncol. 20 (24): 4643–8. PMID 12488408. Text " lymphoma: Radiation Therapy Oncology Group Study 93-10 " ignored (help); Unknown parameter |month= ignored (help)
  21. ↑ Bartlett NL, Rosenberg SA, Hoppe RT, Hancock SL, Horning SJ (1995). "Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report". J. Clin. Oncol. 13 (5): 1080–8. PMID 7537796. Unknown parameter |month= ignored (help)
  22. ↑ Nabholtz JM, Mackey JR, Smylie M; et al. (2001). "Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer". J. Clin. Oncol. 19 (2): 314–21. PMID 11208821. Unknown parameter |month= ignored (help)
  23. ↑ Fleming GF, Brunetto VL, Cella D; et al. (2004). "Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study". J. Clin. Oncol. 22 (11): 2159–66. doi:10.1200/JCO.2004.07.184. PMID 15169803. Unknown parameter |month= ignored (help)
  24. ↑ Tsukasaki K, Utsunomiya A, Fukuda H; et al. (2007). "VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801". J. Clin. Oncol. 25 (34): 5458–64. doi:10.1200/JCO.2007.11.9958. PMID 17968021. Unknown parameter |month= ignored (help)
  25. ↑ Loehrer PJ, Gonin R, Nichols CR, Weathers T, Einhorn LH (1998). "Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor". J. Clin. Oncol. 16 (7): 2500–4. PMID 9667270. Unknown parameter |month= ignored (help)
  26. ↑ Nichols CR, Catalano PJ, Crawford ED, Vogelzang NJ, Einhorn LH, Loehrer PJ (1998). "Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study". J. Clin. Oncol. 16 (4): 1287–93. PMID 9552027. Unknown parameter |month= ignored (help)

External Links

Retrieved from "https://www.wikidoc.org/index.php?title=List_of_chemotherapy_regimens&oldid=1061659"